Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Landos Biopharma

-   Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD) NORTH CHICAGO, Ill. , May 23, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Landos Biopharma, Inc. (NASDAQ: LABP).

AbbVie Completes Acquisition of Landos Biopharma

Eli Lilly

Pfizer

Biotech is one of the most exciting industries to invest in right now. Companies have drugs on the market worth billions and continue to strive to produce the newest and best treatments in modern medicine.

3 Biotech Stocks to Buy on the Dip: May 2024

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why AbbVie (ABBV) is a Top Value Stock for the Long-Term

This company offers growth, high yield, and dividend growth.

A Must-Own Stock for Any Portfolio

ATLANTA--(BUSINESS WIRE)---- $ABBV #Alzamend--Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel.

Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel

AbbVie is bolstering its psychiatry pipeline with an acquisition. The biotech it's acquiring is developing psychedelic-adjacent drugs.

2 Billion More Reasons to Buy AbbVie Stock

Amazon

Walmart

Since 1928, there have been 25 bear markets, or declines in the S&P 500 of 20% or more, according to Yardeni Research. Market corrections have been far more common.

3 S&P 500 Stocks That Have Proven Themselves Recession-Proof

AbbVie's lead drug Humira lost its patent-protected market exclusivity in the U.S. last year. Despite shrinking Humira revenues, AbbVie's first-quarter sales grew thanks to more recently launched blockbusters.

1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165?

-    AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing the standards of care in inflammatory bowel diseases (IBD) -    Data to be presented from the SEQUENCE head-to-head trial comparing risankizumab (SKYRIZI®) versus ustekinumab (STELARA®) in Crohn's disease include an economic analysis and oral presentation that assessed inflammation biomarkers -    Additional presentations include efficacy and safety data evaluating clinical, endoscopic, and histologic outcomes from both the INSPIRE Phase 3 induction study and the COMMAND Phase 3 maintenance study of risankizumab as a therapy for adults with moderately to severely active ulcerative colitis NORTH CHICAGO, Ill. , May 17, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced it is presenting 15 abstracts at the 2024 Digestive Disease Week (DDW) Annual Meeting, being held May 18-21 in Washington, D.C.

AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®

Boeing

CVS Health

Johnson & Johnson

Lockheed Martin

Procter & Gamble

Finding equities with the potential for steady, long-term development is crucial. These seven prospects span a variety of industries and offer solid arguments for long-term investment.

7 Value Stocks to Buy and Hold for a Decade of Dominance

Chevron

Essential Utilities

What could be better than well-established retirement stocks to buy that you can trust? How about adding to that confidence level with the backing of Wall Street analysts.

Wall Street Favorites: 3 Retirement Stocks With Strong Buy Ratings for May 2024

AbbVie, Inc. (NYSE:ABBV ) Bank of America Health Care Conference Call May 15, 2024 1:40 PM ET Company Participants Robert Michael - CEO Roopal Thakkar - SVP, Chief Medical Officer, Global Therapeutics Jeffrey Stewart - COO Conference Call Participants Geoffrey Meacham - Bank of America Merrill Lynch Operator Geoffrey Meacham With me on stage is CEO, Rob Michael, currently President and COO, I guess, but soon to be. Robert Michael Soon to be, yes.

AbbVie, Inc. (ABBV) Bank of America Health Care Conference Call Transcript

Ally Financial

Comcast

Camden Property

Cisco Systems

Discover

DHL Group

Dow Inc

Elevance Health Inc

First American Financial

MetLife

Merck

Nucor

Teleperformance

The April/May 2024 edition of Fortune Magazine revealed its 100 Best Companies To Work For, or Besties. My latest Dogcatcher-quest to sniff-out the best dividend-buys found 56 dividend-paying Besties using YCharts 5/13/24 data.

2 Fortune 100 Best Co's To Work For Are Also Good To Own

AbbVie (ABBV) inks an option-to-license and collaboration deal with Gilgamesh to develop next-generation therapies for psychiatric disorders.

AbbVie (ABBV) Boosts Neuropsychiatric Portfolio With New Deal

Apple

AGNC Investment

Antero Midstream Partners

Apple Hospitality REIT

Ares Capital

Apollo Commercial Real Estate Finance

Broadcom

Alibaba

Bank of America

BASF SE

Brookfield Renewable Partners

B&G Foods

Bank of Montreal

Bayerische Motoren Werke AG

Bank of Nova Scotia

BRT Apartments

Blackstone Group

Blackstone Secured Lending Fund

Colgate-Palmolive

Canadian Imperial Bank of Commerce

Portfolio changes in April focus on BDCs, aiming to increase dividend income by at least $100 each month. Dividend income hit a new all-time record for April of $736, basically flat Y/Y and up 12% sequentially. Gifted Working Time 2024: Around 85 hours, or 10.6 days, of active work have been replaced with passive income in 2024, which is equivalent to more than two entire workweeks.

My Dividend Stock Portfolio: New April Dividend Record - 101 Holdings With 22 Buys

ATLANTA--(BUSINESS WIRE)---- $ABBV #15_Percent_Interest_Bearing_Preferred_Stock--Alzamend Neuro Announces Initial Closing of Private Placement; Investor Purchase Up to $25 Million of Preferred Shares; Proceeds for Clinical Trials.

Alzamend Neuro Announces Initial Closing of Private Placement

Novartis

Eli Lilly is an ideal stock for growth and dividends. AbbVie is a Dividend King with a bright future.

3 Magnificent Stocks That Are Passive Income Machines

AbbVie's best-selling product recently lost its patent protection, threatening the company's future results. The drugmaker's R&D pipeline, however, is more promising than it's getting credit for.

What Is the Dividend Payout for AbbVie Stock?

-   Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders NORTH CHICAGO, Ill. and NEW YORK , May 13, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals today announced a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders.

AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Landos Biopharma, Inc. (NasdaqCM: LABP) to AbbVie Inc. (NYSE: ABBV). Under the terms of the proposed transaction, shareholders of Landos will receive $20.42 in cash, plus one non-tradable contingent value right (with a value of up to $11.14 per share, subject to the achievement of a clinical development milest.

LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP

AT&T

Exxon Mobil

AbbVie is a diversified healthcare company that has been able to strengthen its portfolio via acquisitions. AT&T has faced a lot of negative press in recent years but its fundamentals remain sound.

3 Rock-Solid Dividend Stocks That Are Ideal for Retirees

ATLANTA--(BUSINESS WIRE)---- $ABBV #15_Percent_Interest_Bearing_Preferred_Stock--Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of Up to $25 Million.

Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million

News for AbbVie Stock (ABBV)